 |
|
|
Important Notice: The Alzheimer Research Forum does not
provide medical advice nor promote any product or service. The contents are for
informational purposes only and are not intended to substitute for professional
medical advice, diagnosis or treatment. Always seek advice from a qualified physician
or health care professional about any medical concern, and do not disregard professional
medical advice because of anything you may read on this web site. The views of individuals
quoted on this site are not necessarily those of the Alzheimer Research Forum.
|
RESULTS
(listed alphabetically):
|
|
NAME:
Clioquinol
|
|
OTHER NAMES:
iodochlorhydroxyquin, PBT-1
|
|
FDA PHASE:
Discontinued
|
|
MECHANISMS:
metal-protein-attenuation
|
|
ROLE IN ALZHEIMER'S DISEASE:
Clioquinol inhibits zinc and copper ions from binding to
Aβ, thus promoting the solubilization and clearance
of Aβ. A pilot phase II clinical trial suggests that
clioquinol improves cognition and lowers plasma levels of
Aβ42 in some patients.
|
|
|
|
|
|
|
Home
